SLC5A2 and type 2 diabetes mellitus: This meta-analysis evaluated the effects of SGLT-2 inhibitors on cardiovascular outcomes in patients with T2DM and the results demonstrated that patients treated with SGLT-2 inhibitors, especially as add-on therapy, experienced significant cardioprotective effects and a potentially favorable outcome for all-cause mortality.